Chengdu Betterma Biopharmaceutical

Chengdu Betterma Biopharmaceutical is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based therapies for metabolic diseases and oncology. The company leverages a proprietary technology platform to design multi-target agonists, including dual and triple agonists targeting the GLP-1, GIP, and glucagon receptors. Its lead candidate, BTM-323, is a tri-agonist currently in clinical trials aimed at providing superior weight loss and glycemic control for patients with obesity and type 2 diabetes. Headquartered in Chengdu, China, Betterma focuses on addressing significant unmet medical needs in chronic metabolic conditions through advanced biologics engineering. The company's pipeline reflects a strategic commitment to next-generation treatments for metabolic dysfunction-associated steatohepatitis (MASH) and other endocrine disorders.